Wall Street equity research analysts covering Protalix BioTherapeutics maintain average 12-month consensus price targets ranging from $10.00 to $12.00 per share. These bullish projections reflect anticipated revenue growth from its commercialized enzyme replacement therapies and ongoing clinical pipeline developments, representing substantial potential percentage upside compared to its current trading levels.